List of Azilect drug patents

Azilect is owned by Teva.

Azilect contains Rasagiline Mesylate.

Azilect has a total of 2 drug patents out of which 0 drug patents have expired.

Azilect was authorised for market use on 16 May, 2006.

Azilect is available in tablet;oral dosage forms.

Azilect can be used as treatment of parkinson's disease.

The generics of Azilect are possible to be released after 27 August, 2027.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7815942 TEVA Rasagiline formulations of improved content uniformity
Aug, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7572834 TEVA Rasagiline formulations and processes for their preparation
Dec, 2026

(3 years from now)

Drugs and Companies using RASAGILINE MESYLATE ingredient

Market Authorisation Date: 16 May, 2006

Treatment: Treatment of parkinson's disease

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in